A transient inflammatory response contributes to oxaliplatin neurotoxicity in mice
- PMID: 36369764
- PMCID: PMC9735376
- DOI: 10.1002/acn3.51691
A transient inflammatory response contributes to oxaliplatin neurotoxicity in mice
Abstract
Objectives: Peripheral neuropathy is a relevant dose-limiting adverse event that can affect up to 90% of oncologic patients with colorectal cancer receiving oxaliplatin treatment. The severity of neurotoxicity often leads to dose reduction or even premature cessation of chemotherapy. Unfortunately, the limited knowledge about the molecular mechanisms related to oxaliplatin neurotoxicity leads to a lack of effective treatments to prevent the development of this clinical condition. In this context, the present work aimed to determine the exact molecular mechanisms involved in the development of oxaliplatin neurotoxicity in a murine model to try to find new therapeutical targets.
Methods: By single-cell RNA sequencing (scRNA-seq), we studied the transcriptomic profile of sensory neurons and satellite glial cells (SGC) of the Dorsal Root Ganglia (DRG) from a well-characterized mouse model of oxaliplatin neurotoxicity.
Results: Analysis of scRNA-seq data pointed to modulation of inflammatory processes in response to oxaliplatin treatment. In this line, we observed increased levels of NF-kB p65 protein, pro-inflammatory cytokines, and immune cell infiltration in DRGs and peripheral nerves of oxaliplatin-treated mice, which was accompanied by mechanical allodynia and decrease in sensory nerve amplitudes.
Interpretation: Our data show that, in addition to the well-described DNA damage, oxaliplatin neurotoxicity is related to an exacerbated pro-inflammatory response in DRG and peripheral nerves, and open new insights in the development of anti-inflammatory strategies as a treatment for preventing peripheral neuropathy induced by oxaliplatin.
© 2022 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
Conflict of interest statement
The authors declare no competing interests.
Figures





References
-
- Grothey A, Goldberg RM. A review of oxaliplatin and its clinical use in colorectal cancer. Expert Opin Pharmacother. 2004;5(10):2159‐2170. - PubMed
-
- Hato SV, Khong A, de Vries IJ, Lesterhuis WJ. Molecular pathways: the immunogenic effects of platinum‐based chemotherapeutics. Clin Cancer Res. 2014;20(11):2831‐2837. - PubMed
-
- Argyriou AA, Bruna J, Marmiroli P, Cavaletti G. Chemotherapy‐induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol. 2021;82(1):51‐77. - PubMed
-
- Mols F, Beijers T, Lemmens V, van den Hurk CJ, Vreugdenhil G, van de Poll‐Franse LV. Chemotherapy‐induced neuropathy and its association with quality of life among 2‐ to 11‐year colorectal cancer survivors: results from the population‐based PROFILES registry. J Clin Oncol. 2013;31(21):2699‐2707. - PubMed
-
- Park SB, Lin CS, Krishnan AV, Goldstein D, Friedlander ML, Kiernan MC. Oxaliplatin‐induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain. 2009;132(Pt 10):2712‐2723. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical